CLINICAL AND NEUROLOGICAL FACTORS IN THE FORMATION OF INDIVIDUAL PREDISPOSITION TO COVID-ASSOCIATED ISCHEMIC STROKE
##plugins.themes.academic_pro.article.main##
Abstract
Stroke is currently the leading cause of disability and one of the leading causes of death in the world. Among patients who survived after a stroke, movement disorders are observed by the end of the acute period of stroke in 85% of patients, by the end of the first year - in 70%, speech disorders (aphasia) by the end of the acute period - in 36%, by the end of the first year - in 18% of patients Ischemic stroke accounts for 60% to 80% of all reported cases
##plugins.themes.academic_pro.article.details##

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
- Grabowska-Fudala B., Jaracz K., Gуrna K. Stroke incidence, case fatality and mortality--current trends and future prognosis // Przegl. Epidemiol. — 2010. — №3. — Р. 439-442.
- Hassoun H.T., Malas M.B., Freischlag J.A. Secondary stroke prevention in the era of carotid stenting: update on recent trials // Arch. Surg. — 2010. — №10. — Р.928-935.
- Kaste M. Every day is a world stroke day: act now, be a stroke champion and a torchbearer! // Stroke. — 2010. — №11. — Р. 2449-2250.
- Аст Now. Impementation guidelines for stroke management. — 2010.
- Goldstein L.B., Bushnell C.D., Adams R.J. et al. Guidelines for the primary prevention of stroke. A guideline for healthcare professionals from the American Heart Association // Stroke. — 2010.
- Yarygin K.N., Kholodenko I.V., Konieva A.A. et al. Mechanisms of positive effects of transplantation of human placental mesenchymal stem cells on recovery of rats after experimental ischemic stroke // Bull. Exp. Biol. Med. — 2009. — Vol. 148. — P. 862-868.
- Stadler K. Peroxynitrite-driven mechanisms in diabetes and insulin resistance — the latest advances // Curr. Med. Chem. — 2010.
- Ostrovaya T.V., Cherniy V.I. Cerebroprotection in the aspect of evidence-based medicine // Medicine of emergency conditions. - 2007. - No. 2. - S. 48-53.
- The use of cerebrolysin in cerebral ischemic stroke: Method. Rec. / Ed. Corresponding Member RAMS, prof. V.I.Skvortsova. - M., 2006 .-- 25 p.
- Ginsberg M.D. Adventures in pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection. The Thomas Willis lecture // Stroke. — 2003. — №1. — Р. 214-223.
- Cherniy V.I., Elskiy V.N., Gorodnik G.A. et al. Acute cerebral insufficiency. - Donetsk: Izd. Zaslavsky A.Yu., 2008 .-- 440 p.
- Shtark MB Brain-specific proteins (antigens) and neuron function. - M .: Medicine, 1989.
- Kong D.F., Topol E.J., Bittl J.A. et al. Clinical outcomes of bivalirudin for ischemic heart disease // Circulation. — 1999. — №100. – Р. 2049-2053.